Eli Lilly and Company (LLY)
Track the next or latest earnings date for Eli Lilly and Company, review consensus estimates, and see cached AI analysis for recent quarterly results.
Recent earnings news
stockstory.org · 1 day ago
The bottom line is that over the long term, earnings growth goes hand in hand with the biggest winners. Keeping that in mind, here are three market-beating stocks that deserve a spot on your list. ... Founded in 1876 by a Civil War veteran and pharmacist frustrated with the poor quality of medicines…
Eli Lilly Stock (LLY) Opinions on GLP-1 Drug Expansions | Quiver Quantitativewww.quiverquant.com · 18 hours ago
Cancer Benefits Emerging: Fresh research points to notable reductions in tumor progression and mortality risks for users of Eli Lilly's GLP-1 therapies, including Mounjaro. Observational studies cited in recent reports show halved cancer spread rates alongside a 25 percent lower breast cancer ...
Buy Eli Lilly Stock – LLY Stock Quote Today & Investment Insights - Public.compublic.com · 4 days ago
Looking to buy Eli Lilly Stock? Get the latest LLY quote, news, earnings, forecast, price targets, and market insights. Start investing on Public.com.
Why Is LLY Stock Rising Today?stocktwits.com · 2 days ago
Shares of Eli Lilly and Company (LLY) rose about 1% in pre-market trading on Thursday after the company reported positive topline results from its Phase 3 TRIUMPH-1 study.
Eli Lilly Earnings Call Signals High-Growth Trajectory - TipRanks.comwww.tipranks.com · 3 days ago
Eli Lilly And Company ((LLY)) has held its Q1 earnings call. Read on for the main highlights of the call. Start a conversation with TipRanks’ trusted, data-backed investment intelligence · Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Latest earnings date
Time not specified
Fiscal quarter: 2025-12-31
EPS estimate: $7.49
Revenue estimate: N/A
Market cap: $1014.67B
AI earnings summary
Lilly issued strong 2026 guidance with revenue expected between $80-83 billion (vs analyst estimates of $77.62 billion) and non-GAAP EPS of $33.50-35.00 (vs estimates of $33.23). The midpoint represents 25% revenue growth despite expected global pricing declines from Trump administration deals.
Sentiment and reaction
Sentiment score: +90.00%
Post-earnings price reaction: +7.00%
EPS
Estimate: $7.49
Actual: $7.39
Surprise: -1.34%
Revenue
Estimate: $17.96B
Actual: $19.29B
Surprise: +7.42%
Financial highlights
• Revenue increased 43% to $19.3 billion driven by volume growth from Mounjaro and Zepbound • Net income of $6.6 billion, up 50% year-over-year • Gross margin increased 43% to $15.9 billion (82.5% margin, up 0.3 percentage points) • Mounjaro revenue surged 110% to $7.4 billion in Q4 • Zepbound revenue jumped 122% to $4.2 billion in Q4 • U.S. revenue climbed to $12.9 billion driven by 50% volume increase • International revenue grew 43% to $6.4 billion with 38% volume growth • R&D expenses increased 26% to $3.8 billion (20% of revenue) • Marketing/administrative expenses up 29% to $3.1 billion • Effective tax rate was 19.7% vs 12.5% prior year • Non-GAAP EPS of $7.54 vs $5.32 prior year (42% increase)
Recent earnings history
Browse the calendar week| Date | Quarter | Report window | EPS est. | Revenue est. |
|---|---|---|---|---|
| Feb 05, 2026 | 2025-12-31 | Time not specified | $7.49 | N/A |